Search

Search Results

• 

  Anti-interleukin-17 and anti-interleukin-23 biologic drugs for genital psoriasis: a single-center retrospective comparative study

  Andrea Cortese, Luigi Gargiulo, Luciano Ibba, Giovanni Fiorillo, Francesco Toso, Carlo Alberto Vignoli, Alessandra Narcisi, Antonio Costanzo, Mario Valenti

  19-05-2023

  https://doi.org/10.4081/dr.2023.9692

  1057

  PDF: 546

  HTML: 19
• 

  Implications of interleukin-17 in psoriatic lesions as Koebner phenomenon caused by recurrent occupational burns

  Ayumi Sato, Takeshi Fukumoto, Ai Yoshioka, Chikako Nishigori

  27-10-2022

  https://doi.org/10.4081/dr.2022.9567

  991

  PDF: 514

  HTML: 15
• 

  Lentiginous eruption in resolving psoriasis plaques during treatment with ixekizumab: a case report and review of the literature

  Pablo Santa María, Fernando Valenzuela, Claudia Morales, Raul De la Fuente, Roberto Cullen

  11-10-2017

  https://doi.org/10.4081/dr.2017.7079

  1377

  PDF: 661

  HTML: 142
• 

  Long term efficacy, safety, and tolerability of tildrakizumab in epileptic patient with psoriasis and eczema

  Nicoletta Bernardini, Nevena Skroza, Giovanni Rossi, Alessandra Mambrin, Ersilia Tolino, Federica Marraffa, Martina Caviglia, Antonio Di Guardo, Salvatore Volpe, Ilaria Proietti, Concetta Potenza

  21-11-2022

  https://doi.org/10.4081/dr.2022.9447

  1306

  PDF: 405

  HTML: 45

• Tildrakizumab in the treatment of plaque psoriasis in an HIV+ patient: a case report and literature review of anti-interleukin drugs

  Viviana Lora, Dario Graceffa, Monia Di Prete, Carlo Cota

  11-11-2024

  https://doi.org/10.4081/dr.2024.10140

  989

  PDF: 521

  SUPPLEMENTARY MATERIAL: 153

  HTML: 16

• Biologics and small molecules treatment for moderate-to-severe atopic dermatitis patients with comorbid conditions and special populations: an Italian perspective

  Alba Guglielmo, Maria Ludovica Deotto , Luigi Naldi , Giuseppe Stinco, Alessandro Pileri, Bianca Maria Piraccini, Anna Belloni Fortina, Andrea Sechi

  13-09-2023

  https://doi.org/10.4081/dr.2023.9839

  2686

  PDF: 982

  HTML: 31

• Refractory pityriasis rubra pilaris treated with abrocitinib

  Filip Rob

  09-01-2025

  https://doi.org/10.4081/dr.2025.10105

  406

  PDF: 273

  HTML: 11
• 

  Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis

  Luca Mastorino, Niccolò Siliquini, Gianluca Avallone, Michela Ortoncelli, Pietro Quaglino, Paolo Dapavo, Simone Ribero

  17-03-2022

  https://doi.org/10.4081/dr.2022.9282

  1162

  PDF: 825

  HTML: 41
• 

  Dimethyl fumarate as a safe and effective therapy for recalcitrant psoriasis in comorbid patients

  Martina Burlando, Mattia Fabio Molle, Emanuele Cozzani, Aurora Parodi

  14-03-2022

  https://doi.org/10.4081/dr.2022.9091

  2625

  PDF: 632

  HTML: 6
• 

  Herpes vegetans, an atypical herpes lesion in HIV patient: A case report

  Sondang P. Sirait, Wresti Indriatmi

  14-03-2022

  https://doi.org/10.4081/dr.2022.9180

  2632

  PDF: 829

  HTML: 16

• A severe psoriasis flare after COVID-19 treated with risankizumab: complete skin clearance after 16 weeks

  Luciano Ibba, Luigi Gargiulo, Giulia Pavia, Alessandra Narcisi, Antonio Costanzo, Mario Valenti

  06-06-2023

  https://doi.org/10.4081/dr.2023.9722

  792

  PDF: 460

  HTML: 17

• Does the response to bimekizumab vary according to previous therapy with methotrexate versus cyclosporine?

  Ilaria Salvi, Alexandra M. G. Brunasso, Franco Castelli, Andrea Michelerio, Paolo Pella, Marco Rubatto, Paolo Dapavo, Emanuele Cozzani, Martina Burlando

  20-03-2026

  https://doi.org/10.4081/dr.2026.10236

  214

  PDF: 149

• Upadacitinib as a potential option for the management of paradoxical eczema induced by interleukin-23 inhibitors

  Anna Paola Lugli, Niccolò Gori, Elena Ippoliti, Benedetta Ambrosio, Ketty Peris

  03-02-2026

  https://doi.org/10.4081/dr.2026.10644

  532

  PDF: 301